LifeStance Health Group Inc. (NASDAQ: LFST) experienced an 11.6% decline in premarket trading Friday after the company disclosed pricing for a secondary share sale by existing stockholders. The offering is set at 35 million shares, each priced at $8.15.
The company said the sale is being carried out by current holders of its stock; LifeStance will not issue new shares and will not receive any of the sale proceeds. Separately, LifeStance will repurchase 6 million shares from the selling stockholders at the same price paid by the underwriter, with that repurchase contingent on the offerings completion and the satisfaction of customary conditions. The offering itself is not conditioned on the repurchase taking place.
J.P. Morgan is serving as the underwriter for the transaction. The underwriter will not receive compensation for the shares that the company may purchase in the repurchase.
Both the secondary offering and the potential repurchase are expected to settle and close on or about May 12, 2026, subject to customary closing conditions. The shares are being sold under a shelf registration statement filed with the Securities and Exchange Commission.
LifeStance operates as one of the nations largest providers of virtual and in-person outpatient mental health care services.
Summary
LifeStance priced a secondary offering of 35 million existing shares at $8.15 each. The company will not receive proceeds from that sale but plans to repurchase up to 6 million shares from the sellers at the same per-share price paid by the underwriter. J.P. Morgan is the underwriter, and the transactions are expected to settle on or about May 12, 2026.
Key points
- Stock reaction: LFST shares fell 11.6% in premarket trading Friday following the pricing announcement.
- Structure of the deal: The offering involves existing holders selling 35 million shares; LifeStance is not issuing new shares and will not receive sale proceeds.
- Repurchase and logistics: The company will repurchase 6 million shares from selling stockholders at the same price paid by the underwriter; settlement is expected on or about May 12, 2026, pending customary closing conditions.
Risks and uncertainties
- Market reaction risk - The immediate decline of 11.6% in premarket trading indicates potential volatility in LFST equity around the offering announcement, which could affect liquidity and trading sentiment in the short term.
- Execution risk - The repurchase of 6 million shares is subject to the offering closing and customary conditions, meaning the repurchase may not occur even if the offering completes; this creates uncertainty about net share count and investor expectations.
- Perception risk in healthcare and equity markets - Because the offering is by existing stockholders and the company will not receive proceeds, investors may interpret the transaction in ways that influence sentiment across mental health care names and broader healthcare equities.